ロード中...
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
We report a case of a 38-year-old woman who was diagnosed with stage IV lung adenocarcinoma, harboring an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790 M mutation on exon 20. The patient was treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor (E...
保存先:
| 出版年: | Invest New Drugs |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5306260/ https://ncbi.nlm.nih.gov/pubmed/27599705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0389-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|